Distrupt Stiffness Trial

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

April 20, 2026

Study Completion Date

June 20, 2026

Conditions
PAD - Peripheral Arterial DiseasePAD
Interventions
DEVICE

Intravascular Lithotripsy (IVL) plus DCB

"The device under investigation is the Peripheral Lithotripsy System (Shockwave Medical, Fremont, California). Miniaturized and arrayed lithotripsy emitters create a localized field effect at the site of the calcium. The Peripheral Lithotripsy System is CE-marked for peripheral arterial disease and for this study, will be used within its indication for use. This included the following: intended for lithotripsy-enhanced balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral and popliteal arteries.~The IVL catheter is delivered across a calcified lesion over an 0.014'' wire and the integrated balloon is expanded to 4atm to facilitate efficient energy transfer.~An electrical discharge from the emitters vaporizes the fluid within the balloon, creating a rapidly expanding and collapsing bubble that generates sonic pressure waves. The waves create a localized field effect that travels through soft vascular tissue,"

DEVICE

POBA plus DCB

Standard of Care

Trial Locations (2)

45147

NOT_YET_RECRUITING

West German Heart and Vascular Center, Clinic for Cardiology and Vascular Medicine, Universtiy Hospital Essen, Essen

RECRUITING

University of Duisburg-Essen, Essen

All Listed Sponsors
collaborator

Shockwave Medical, Inc.

INDUSTRY

lead

University Hospital, Essen

OTHER

NCT07130526 - Distrupt Stiffness Trial | Biotech Hunter | Biotech Hunter